{"article_title": "Apotex Sends Latest Biosimilar Application To FDA", "article_keywords": ["fda", "sends", "win", "apotex", "application", "unit", "version", "york", "view", "using", "biosimilar", "neupogen", "latest"], "article_url": "http://www.law360.com/articles/622700/apotex-sends-latest-biosimilar-application-to-fda", "article_text": "Apotex Sends Latest Biosimilar Application To FDA\n\nLaw360, New York (February 18, 2015, 4:53 PM ET) -- Apotex Inc. on Tuesday announced that the U.S. Food and Drug Administration has accepted its application for a copycat version of Amgen Inc.\u2019s blockbuster biologic Neupogen, marking the agency\u2019s fifth known review using the Affordable Care Act's biosimilars pathway.\n\n\n\nCanada-based Apotex is the second company to propose a biosimilar version of Neupogen, or filgrastim, which supports immune health during chemotherapy. It follows Novartis AG unit Sandoz Inc., which is on track to become the first drugmaker to win approval along the ACA route.\n\n\n\nTuesday\u2019s biosimilar application...\n\nTo view the full article, register now.", "article_metadata": {"description": "Apotex Inc. on Tuesday announced that the U.S. Food and Drug Administration has accepted its application for a copycat version of Amgen Inc.&rsquo;s blockbuster biologic Neupogen, marking the agency&rsquo;s fifth known review using the Affordable Care Act&#39;s biosimilars pathway.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/622700/apotex-sends-latest-biosimilar-application-to-fda", "csrf-token": "R/xFbugXcedjI+J3okL4Tab5RIZcPE21HXGGucX899ILuMz5n8Bnq57I30s4n2TrtNhGAIV6AZKFhb4MAeqvcg==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/622700/apotex-sends-latest-biosimilar-application-to-fda", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Apotex Sends Latest Biosimilar Application To FDA - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fe2330\"", "article_summary": "Canada-based Apotex is the second company to propose a biosimilar version of Neupogen, or filgrastim, which supports immune health during chemotherapy.\nApotex Sends Latest Biosimilar Application To FDALaw360, New York (February 18, 2015, 4:53 PM ET) -- Apotex Inc. on Tuesday announced that the U.S. Food and Drug Administration has accepted its application for a copycat version of Amgen Inc.\u2019s blockbuster biologic Neupogen, marking the agency\u2019s fifth known review using the Affordable Care Act's biosimilars pathway.\nTuesday\u2019s biosimilar application...To view the full article, register now.\nIt follows Novartis AG unit Sandoz Inc., which is on track to become the first drugmaker to win approval along the ACA route."}